Epiville

Quizzes

Quiz 4, Module Randomized

4. Based on the table above, which of the following represents an appropriate method to analyze whether KimFaderol treatment is associated with preventing the progression to Stage III of Susser Syndrome in this population?

  1. Compare the incidence proportion of Stage III Susser Syndrome in the KimFaderol group to the incidence proportion of Stage III Susser Syndrome in the placebo group.
  2. Conduct a functional MRI scan of all individuals developing severe symptoms and compare the results of the scan between those assigned to KimFaderol and those assigned to placebo.
  3. Compare the rate of symptom appearance in the KimFaderol group to the rate of symptom appearance in the placebo group.
Answer (a) — correct: Since we are assessing whether the experimental treatment prevents the occurrence of impaired proprioception (which defines the occurrence of Stage III Susser Syndrome) we can compare the incidence proportion of new severe symptoms between the two groups.
Answer (b) — incorrect: We do not need to perform any more diagnostic tests in order to assess our hypothesis. We are interested in whether KimFaderol prevents impaired proprioception (as assessed by the neurologist), and do not need a fMRI to tell us this.
Answer (c) — incorrect: We have no information on person-time of observation, and no information on the time of occurrence of symptoms, since we assessed outcome only once, 12 month after the start of the treatment. Therefore we cannot calculate rates.